{"id":"ahb-137","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, AHB-137 reduces glucose reabsorption in the kidneys, lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"AHB-137 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:00:16.048Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07370207","phase":"PHASE2","title":"Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region","status":"NOT_YET_RECRUITING","sponsor":"AusperBio Therapeutics Inc.","startDate":"2026-02-02","conditions":"Hepatitis B, Chronic","enrollment":84},{"nctId":"NCT06993480","phase":"PHASE2","title":"A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)","status":"RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","startDate":"2025-06-18","conditions":"Chronic Hepatitis B","enrollment":30},{"nctId":"NCT07246889","phase":"PHASE3","title":"Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","startDate":"2025-08-12","conditions":"Chronic Hepatitis B","enrollment":577},{"nctId":"NCT06550128","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","startDate":"2024-07-10","conditions":"Hepatitis B, Chronic","enrollment":86},{"nctId":"NCT07069569","phase":"PHASE2","title":"A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","startDate":"2025-05-30","conditions":"Chronic Hepatitis B","enrollment":127},{"nctId":"NCT06115993","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","startDate":"2023-08-03","conditions":"Hepatitis B, Chronic","enrollment":129},{"nctId":"NCT06829329","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","startDate":"2024-12-13","conditions":"Chronic Hepatitis B","enrollment":105},{"nctId":"NCT07146100","phase":"","title":"Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection","status":"NOT_YET_RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","startDate":"2025-08-21","conditions":"Chronic Hepatitis B","enrollment":200},{"nctId":"NCT07137910","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)","status":"NOT_YET_RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","startDate":"2025-08-27","conditions":"Chronic Hepatitis B","enrollment":60},{"nctId":"NCT05717686","phase":"PHASE1","title":"A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B","status":"COMPLETED","sponsor":"AusperBio Therapeutics Inc.","startDate":"2023-02-28","conditions":"Chronic Hepatitis B","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AHB-137","genericName":"AHB-137","companyName":"AusperBio Therapeutics Inc.","companyId":"ausperbio-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AHB-137 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}